EGFR and head and neck squamous cell carcinoma: To further explore the influence of EGFR signalling on the potential of HNSCC cells to escape anoikis and to survive in forced suspension, the four cell lines were either treated with EGFR ligands (100ng/ml AREG or EGF), the EGFR-blocking antibody cetuximab (CTX, 100μg/ml) or the EGFR-specific tyrosine-kinase inhibitor gefitinib, for 72h.